Cambridge Investment Research Advisors
PRPH

Cambridge Investment Research Advisors’s ProPhase Labs PRPH Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,480
Closed -$7K – 3929
2025
Q3 		$7K Buy
+1,480
New +$5.72K ﹤0.01% 3708
2023
Q1 		– Sell
-3,074
Closed -$296K – 3229
2022
Q4 		$296K Buy
3,074
+568
+23% +$61.4K ﹤0.01% 2442
2022
Q3 		$283K Buy
2,506
+1,185
+90% +$138K ﹤0.01% 2410
2022
Q2 		$168K Buy
+1,321
New +$116K ﹤0.01% 2763

Other funds holding PRPH

SC
Sykon Capital Harrison, New York $325M AUM 19.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Cambridge Investment Research Advisors's PRPH Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of ProPhase Labs (PRPH) in Q4 2025, closing a stake of 1,480 shares — an estimated $7K sold.

Cambridge Investment Research Advisors first reported a position in PRPH in Q2 2022 and held it in 4 quarters. The position peaked at $296K in Q4 2022. 17 funds tracked by Wall St. Rank hold PRPH as of Q4 2025.

  • Cambridge Investment Research Advisors reported no remaining ProPhase Labs position as of Q4 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,480 ProPhase Labs shares in Q4 2025, an estimated $7K.
  • Cambridge Investment Research Advisors first reported a position in ProPhase Labs in Q2 2022 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's ProPhase Labs position peaked at $296K in Q4 2022.
  • 17 funds tracked by Wall St. Rank held ProPhase Labs as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.